Matching articles for "macitentan"
In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists
The Medical Letter on Drugs and Therapeutics • September 15, 2025; (Issue 1737)
The FDA has removed the Risk Evaluation and
Mitigation Strategy (REMS) requirement for the
endothelin receptor antagonists ambrisentan (Letairis,
and generics), bosentan (Tracleer, and generics),
macitentan...
The FDA has removed the Risk Evaluation and
Mitigation Strategy (REMS) requirement for the
endothelin receptor antagonists ambrisentan (Letairis,
and generics), bosentan (Tracleer, and generics),
macitentan (Opsumit, and generics; Opsynvi), and
aprocitentan (Tryvio), and the endothelin receptor
antagonist and angiotensin II receptor antagonist
sparsentan (Filspari) that was initially implemented
because of a possible risk of embryofetal toxicity.
Aprocitentan (Tryvio) for Hypertension
The Medical Letter on Drugs and Therapeutics • June 10, 2024; (Issue 1704)
The FDA has approved the dual endothelin receptor
antagonist aprocitentan (Tryvio – Idorsia) for
use in combination with other antihypertensive
drugs to treat hypertension in adults whose blood
pressure...
The FDA has approved the dual endothelin receptor
antagonist aprocitentan (Tryvio – Idorsia) for
use in combination with other antihypertensive
drugs to treat hypertension in adults whose blood
pressure is not adequately controlled on other drugs.
Three other dual endothelin receptor antagonists,
ambrisentan (Volibris, and generics), bosentan
(Tracleer, and generics), and macitentan (Opsumit),
are available in the US for treatment of pulmonary
arterial hypertension.
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024; (Issue 1702)
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • February 15, 2016; (Issue 1488)
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral...
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral prostacyclin analog,
was approved earlier for this indication.
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • January 4, 2016; (Issue 1485)
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this...
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this indication.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • March 3, 2014; (Issue 1437)
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • February 17, 2014; (Issue 1436)
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist...
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist approved for PAH. It is a derivative
of bosentan (Tracleer), which is also manufactured
by Actelion, and is scheduled to become available generically
in 2015. Riociguat (Adempas), another new drug for
this indication, will be reviewed in a future issue.
Volibris